Passage BIO (PASG) Cash & Equivalents (2019 - 2026)

Passage BIO's Cash & Equivalents history runs 8 years deep, the most recent figure standing at $33.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 47.44% year-over-year to $33.3 million; the TTM figure through Mar 2026 stood at $33.3 million (down 47.44% YoY), while the FY2025 annual figure was $46.3 million, up 23.23% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $33.3 million, down from $46.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $101.6 million in Q1 2022, with the low at $21.7 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $36.8 million (2024), against an average of $46.7 million.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents slumped 73.17% in 2022, then jumped 132.64% in 2025.
• Passage BIO's Cash & Equivalents stood at $34.6 million in 2022, then plunged by 37.26% to $21.7 million in 2023, then surged by 73.08% to $37.6 million in 2024, then climbed by 23.23% to $46.3 million in 2025, then fell by 28.08% to $33.3 million in 2026.
• Business Quant data shows PASG's Cash & Equivalents at $33.3 million in Q1 2026, $46.3 million in Q4 2025, and $52.8 million in Q3 2025.